

Diversion and Street Price of XTAMPZA® ER Relative to Other Prescription Opioids

Severtson SG¹, Margolin ZR¹, Iwanicki JL¹, Dart RC¹ ¹Rocky Mountain Poison & Drug Safety - Denver Health, Denver, CO



INTRODUCTION

- Many individuals who abuse prescription opioids obtain these medications after they are diverted from legal distribution channels
- The frequency of diversion of a product and the price paid in illegal markets may be indicators of the demand among individuals who abuse opioids
- This study assesses the extent of diversion and average street price paid for XTAMPZA® ER, an abuse deterrent extended-release (ER) oxycodone product that uses DETERx® technology designed to discourage product manipulation for misuse and abuse by oral and non-oral routes

METHODS

- Data from 2018 through 2020 from two Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System data sources:
 - **Drug Diversion Program:** obtains information on new cases of diversion reported by law enforcement and regulatory agencies in 49 states. Rates of diversion cases using two utilization measures (prescriptions dispensed and morphine equivalent grams) dispensed were compared between drug groups. Both estimates were obtained from the IQVIA® (Danbury, CT) US-Based Longitudinal Prescription Data
 - **StreetRx Program:** collects black market drug price information via anonymous submissions to StreetRx.com. The geometric mean price per milligram strength was compared between drug groups. Unadjusted geometric mean street price and geometric mean street price adjusted for tablet strength and active pharmaceutical ingredient were assessed
- XTAMPZA ER was compared to two groups: other abuse deterrent formulation (ADF) ER opioids, and immediate-release (IR) oxycodone (Table 1)

DISCLOSURE

The RADARS® System is supported by subscriptions from pharmaceutical manufacturers, government and non-government agencies for surveillance, research and reporting services. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases and systems. Subscribers do not participate in data collection nor do they have access to the raw data. This research was sponsored by Collegium Pharmaceutical. XTAMPZA® ER is a registered trademark of Collegium Pharmaceutical.

RESULTS

Table 1. Prescriptions Dispensed by Drug Group, 2018-2020

Drug Group	Prescriptions Dispensed	Percentage within Drug Group
XTAMPZA® ER	1,266,095	100.0%
Other ADF ER Opioids	6,432,576	100.0%
ARYMO® ER	15,784	0.3%
EMBEDA®	256,241	4.0%
HYSINGLA® ER	489,934	7.6%
MORPHABOND® ER	93,170	1.5%
OXYCONTIN®	5,577,447	86.7%
IR Oxycodone	116,248,823	100.0%
Combination	68,423,877	58.9%
Single Entity	47,824,946	41.1%

Figure 1: Ratio of Diversion Rates Relative to XTAMPZA ER by Drug Group with 95% CI, RADARS® System Drug Diversion Program, 2018 – 2020




Table 2: Unadjusted and Adjusted Geometric Mean Price per mg by Drug Group, RADARS® System StreetRx Program, 2018 – 2020

Drug Group	Unadjusted Geometric Mean Street Price per mg (95% CI)	Relative Differences in Adjusted Geometric Mean Street Price per mg* (95 CI, p-value)
XTAMPZA® ER	\$0.57 (\$0.50-0.66)	Reference
Other ADF ER Opioids	\$0.53 (\$0.49-0.56)	-17.9% (-5.4 to -28.9, p=0.007)
IR Oxycodone	\$1.07 (1.04-1.09)	-11.4% (1.3 to -22.4, p=0.077)

*Adjusted for tablet strength and active pharmaceutical ingredient

KEY RESULTS

- Diversion rates for both utilization estimates were statistically significantly greater for comparator drug groups relative to XTAMPZA ER (Figure 1)
- Unadjusted geometric mean street price for XTAMPZA ER was similar to Other ADF ER Opioids
- The geometric mean street price for XTAMPZA ER after adjusting for tablet strength and active pharmaceutical ingredient was significantly lower than other ADF ER Opioids (Table 2)

CONCLUSIONS

- Diversion of XTAMPZA ER was observed, though it comprised a smaller number of cases than would be expected based on prescription volume and drug potency
- The street price of XTAMPZA ER was significantly lower than other ADF ER opioids after adjusting for differences in tablet strength and active pharmaceutical ingredient

LIMITATIONS

- The Drug Diversion Program is not a representative sample and may be affected by regional differences in law enforcement efforts.
- StreetRx prices are self-reported and subjective to recall and recognition biases.
- These data represent information from a limited period.